Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT

Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT

Background: The comparative efficacy, and cost-effectiveness, of imiquimod or podophyllotoxin cream, either alone or in combination with the quadrivalent HPV vaccine (Gardasil®, Merck Sharp & Dohme Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA) in the treatment and prevention of recu...

Full description

Bibliographic Details
Main Authors: Richard Gilson, Diarmuid Nugent, Kate Bennett, Caroline J Doré, Macey L Murray, Jade Meadows, Lewis J Haddow, Charles Lacey, Frank Sandmann, Mark Jit, Kate Soldan, Michelle Tetlow, Emilia Caverly, Mayura Nathan, Andrew J Copas
Format: Article
Language:English
Published: NIHR Journals Library 2020-09-01
Series:Health Technology Assessment
Subjects:
human papillomavirus
anogenital warts
podophyllotoxin
imiquimod
quadrivalent hpv vaccine
randomised controlled trial
Online Access:https://doi.org/10.3310/hta24470

Internet

https://doi.org/10.3310/hta24470

Similar Items